Lorecivivint injection improved responder outcomes in subjects with knee osteoarthritis from ptga Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Lorecivivint, a novel intra-articular Wnt pathway modulator in development as a potential knee osteoarthritis treatment, improved the odds of subjects achieving clinical threshold responses over placebo. n n[PRESENTING AUTHOR NAME] Jeyanesh Tambiah, MD (Samumed, LLC) n[CONTRIBUTING AUTHOR NAMES] Sarah Kennedy, PhD, Christopher J. Swearingen, PhD, Ismail Simsek, MD (Samumed, LLC) n n[ABSTRACT] Introduction: In knee osteoarthritis (OA) trials, discrete threshold responses may demonstrate the clini
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)